Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003849 · ClinicalTrials.gov registry record · Phase 2
Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
- 20
- Study locations
NCT00003849: Completed Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
NCT00003849 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 39 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003849, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have non-Hodgkin's lymphoma or Hodgkin's disease.
Conditions Studied
Interventions
- BIOLOGICAL rituximab
Study Locations (20)
Minnesota
- CCOP - Duluth - Duluth
- Mayo Clinic Cancer Center - Rochester
- CentraCare Clinic - Saint Cloud
- CCOP - Metro-Minnesota - Saint Louis Park
Iowa
- CCOP - Cedar Rapids Oncology Project - Cedar Rapids
- CCOP - Iowa Oncology Research Association - Des Moines
- Siouxland Hematology-Oncology - Sioux City
North Dakota
- Quain & Ramstad Clinic, P.C. - Bismarck
- CCOP - Merit Care Hospital - Fargo
- Altru Health Systems - Grand Forks
Illinois
- CCOP - Illinois Oncology Research Association - Peoria
- CCOP - Carle Cancer Center - Urbana
South Dakota
- Rapid City Regional Hospital - Rapid City
- CCOP - Sioux Community Cancer Consortium - Sioux Falls
Arizona
- CCOP - Scottsdale Oncology Program - Scottsdale
Kansas
- CCOP - Wichita - Wichita
Louisiana
- CCOP - Ochsner - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 1999-07 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
What the finished NCT00003849 record still lists
NCT00003849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which rituximab is the first listed.
NCT00003849 names 20 study sites across 11 states, led by Minnesota, Iowa, North Dakota.
Frequently Asked Questions
What is clinical trial NCT00003849 about?
NCT00003849 is a clinical study titled "Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease". RATIONALE: Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to them. PURPOSE: Phase II trial to study the effectiveness of rituximab in treating patients who have non-Hodgkin's lymphoma or Hodgkin's disease.
What is the current status of trial NCT00003849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 1999-07. Estimated completion is 2008-02.
What conditions does trial NCT00003849 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00003849?
The interventions under investigation include: rituximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003849?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00003849 being conducted?
This trial has 20 study locations across Arizona, Illinois, Iowa, Kansas, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00003849's enrollment target sits among peer trials
39 185th of 299 higher than 111 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia